Neurol. praxi. 2014;15(4):192-196
Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis
- Neurologická klinika 2. LF UK a FN Motol, Praha
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS), with neurodegeneration occurring from the very onset of the disease. With timely treatment, it is possible to slow down the whole immunopathological process. Therefore, treatment is best initiated at the first sign of disease or in the stage of relapsing-remitting MS (RRMS). In such a case, first-choice drugs are used (disease-modifying drugs – DMD). Escalation is required in patients with an insufficient effect of this treatment. For this purpose, either intravenous natalizumab or oral fingolimod are available. So far, none of the above-mentioned drugs has been shown to provide the optimal combination of efficacy with good tolerance and safety while targeting both the inflammation and the process of neurodegeneration. Dimethyl-fumarate (Tecfidera®), which was registered for the treatment of RRMS in the EU on 3rd February 2014, seems to meet these requirements most closely. The results of the ongoing postregistered clinical trials confirm if the dimethyl fumarate is anticipated to have the potential to be classified as the drug of first choice in patients with RRMS.
Keywords: multiple sclerosis, neurodegeneration, neuroprotection, dimethyl fumarate, BG-12, first-choice drugs, DMD
Published: September 1, 2014 Show citation
References
- Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087-1097.
Go to original source... 
Go to PubMed... - Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT. DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098-1107. Go to original source... Go to PubMed...
- Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134(Pt 7): 1914-1924. Go to original source... Go to PubMed...
- Havrdova E, Hutchinson M, Kurukulasuriya NC, Raghupathi K, Sweetser MT, Dawson KT, Gold R. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiplesclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098-1107. Go to original source... Go to PubMed...
- Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010; 74(Suppl 3): S3-7. Go to original source... Go to PubMed...
- Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Efficacy and safetyof oral fumarate in patients with relapsing-remitting multiple sclerosis: amulticentre, randomised, double-blind, placebo-controlled phase IIb study.Lancet. 2008; 372(9648): 1463-1472. Go to original source... Go to PubMed...
- Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, Kong AN. Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis. Biochem Pharmacol. 2008; 76(11): 1485-1489. Go to original source... Go to PubMed...
- Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Brück W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134(Pt 3): 678-692. Go to original source... Go to PubMed...
- PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352(9139): 1498-1504. Go to original source...
- Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, Rhodes KJ. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012; 341(1): 274-284. Go to original source... Go to PubMed...
- Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, Przuntek H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13(6): 604-610. Go to original source... Go to PubMed...
- Schulze-Topphoff U, Varrin-Doyer M, Pekarek R, et al. Dimethyl fumarate utilizes Nrf2-independent and Nrf2-dependent pathways for immune modulation [abstract no. P565]. 29th Congress of the European Committee for Research and Treatment in MultipleSclerosis; 2-5 Oct 2013; Copenhagen.
- Schweckendiek W. Behandlung von psoriasis mit lipoidloslichen fumarsaureverbindungen. Medizin Heute 1966; 15: 219-220.
- Siddiqui MA, Wellington K. Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis. CNS Drugs. 2005; 19(1): 55-61; discussion 63-64. Go to original source... Go to PubMed...
- The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45(7): 1277-1285. Go to PubMed...
- Weinshenker BG, Bass B, Rice GP, oseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989; 112(Pt 1): 133-146. Go to original source... Go to PubMed...